Linked Life Data

18001807

Source:http://linkedlifedata.com/resource/pubmed/id/18001807

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-21
pubmed:abstractText
L-Dopa-induced dyskinesias (LIDs), the disabling abnormal involuntary movements induced by chronic use of L-Dopa, limit the quality of life in Parkinson's disease (PD) patients. Modulation of group II metabotropic glutamate receptors (mGluR2/3) in the basal ganglia, a brain region critically involved in motor control, is considered as an alternative approach in therapy of PD. In this study, receptor binding autoradiography of [3H]LY341495, a mGluR2/3 selective radioligand, was used to investigate possible changes in mGluR2/3 in the basal ganglia of L-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs were prevented by adjunct treatments with CI-1041, a selective antagonist of the NR1A/2B subtype of NMDA receptor, or low doses of the dopamine D2 receptor agonist, cabergoline. Our study is the first to provide evidence of: (1) the similar localization of [3H]LY341495 specific binding to mGluR2/3 in the primate basal ganglia as compared to receptor distribution measured by immunohistochemistry in human and rat as well as this ligand binding in intact rat brain; (2) no change of [3H]LY341495 specific binding in basal ganglia after nigrostriatal denervation by MPTP; and (3) a widespread reduction of [(3)H]LY341495 specific binding to mGluR2/3 in the caudate nucleus (-17% to -31%), putamen (-12% to -45%) and globus pallidus (-56 to -59%) of non-dyskinetic animals treated with L-Dopa+cabergoline as compared to controls, MPTP monkeys treated with saline, L-Dopa alone (dyskinetic) or L-Dopa+CI-1041 (non-dyskinetic). This study is the first to propose a close interaction between mGluR2/3 and dopamine D2 receptors activation in the basal ganglia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0028-3908
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
258-68
pubmed:dateRevised
2008-6-9
pubmed:meshHeading
pubmed-meshheading:18001807-Amino Acids, pubmed-meshheading:18001807-Animals, pubmed-meshheading:18001807-Antiparkinson Agents, pubmed-meshheading:18001807-Autoradiography, pubmed-meshheading:18001807-Basal Ganglia, pubmed-meshheading:18001807-Behavior, Animal, pubmed-meshheading:18001807-Caudate Nucleus, pubmed-meshheading:18001807-Data Interpretation, Statistical, pubmed-meshheading:18001807-Dyskinesia, Drug-Induced, pubmed-meshheading:18001807-Ergolines, pubmed-meshheading:18001807-Excitatory Amino Acid Antagonists, pubmed-meshheading:18001807-Female, pubmed-meshheading:18001807-Levodopa, pubmed-meshheading:18001807-Macaca fascicularis, pubmed-meshheading:18001807-Ovariectomy, pubmed-meshheading:18001807-Putamen, pubmed-meshheading:18001807-Receptors, Metabotropic Glutamate, pubmed-meshheading:18001807-Xanthenes
pubmed:year
2008
pubmed:articleTitle
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
pubmed:affiliation
Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't